NexoBrid ® is a topically administered biological orphan drug that enzymatically removes eschar while preserving viable tissue in patients with deep partial- and full-thickness thermal burns. It is ...

MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced ...

MediWound (MDWD) announced the publication of its Phase III Children Innovative Debridement Study in Burns, the peer-reviewed Journal of the ...

Valeo Financial Advisors LLC cut its stake in Vericel Co. (NASDAQ:VCEL – Free Report) by 19.7% during the 4th quarter, ...

MediWound’s first drug, NexoBrid ®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for ...

MediWound's first drug, NexoBrid ®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for ...

MediWound currently markets NexoBrid which is approved for eschar removal in adult and pediatric patients with deep partial thickness and/or full thickness thermal burns in several geographies ...

We trained a convolutional neural network (CNN) to classify four burn severities: SPF (superficial), SPT (superficial partial thickness), DPT (deep partial thickness), and FT (full thickness).